The graph above demonstrates the control of HBV viremia in the blood of patients under NAP therapy (as measured in copies per ml (cpm) of HBV DNA in the serum) obtained in 8 out of 9 patients treated sequentially with REP 9AC’ alone followed by REP 9AC’ and immunotherapy given in combination for a duration of 12 to 26 weeks.The achievement of total control of HBV infection (HBV DNA < 116 cpm) after therapy in such a large percentage of patients has been previously unachievable with any currently approved treatment for HBV and highlights the promise of REP 9AC’ for the treatment of all patients with HBV infection.
REPLICor publishes the initial pre-clinical development of its NAP technology, including REP 9AC, for the treatment of chronic HBV infection.
Stay in touch. Sign up for our eNewsletter for periodic updates from REPLICor.
We will not share your email address. We are doctors and scientists and understand the concept of privacy.